View the Latest Edition of BioNetwork Here

BioNetwork West 2016 (past event)

October 05 - 07, 2016

1.888.482.6012

The Latest Trends in Biopharma Partnering

Pre-Event Networking Activity The Latest Trends in Biopharma Partnering Innovative Dealmaking Day Three: Connecting Dealmakers

+ Show All Session Details

07:40 - 08:40 Registration And Networking Breakfast

08:40 - 08:45 Welcoming Remarks

08:45 - 09:00 Chairperson’s Opening Address

Speaker:
Jonathan Gertler Managing Partner & CEO Back Bay Life Science Advisors

Jonathan Gertler

Managing Partner & CEO
Back Bay Life Science Advisors

See Bio

09:00 - 09:20 Therapeutic Focus Area Ice Breaker Roundtables

Speakers:
Todd Haim Program Director NIH, National Cancer Institute, Small Business Innovation Research (SBIR) Development Center
Joe Whalen Senior Vice President, Business Development and Alliance Management Horizon Pharma
Kia Motesharei Head, Global Licensing & Business Development, Immunology EMD Serono / Merck KGaA
Paul Resnick Vice President and Chief Business Officer MabVax Therapeutics
Kathryn Gregory Executive Director, Business Development Purdue Pharma

Kick-start your partnering experience meeting those who prioritize the same therapeutic areas as you! Find out the latest priorities in the biggest therapeutic areas and current opportunities available. Discuss goals, common industry challenges and firm up your personal partnering objectives for the next three days.

#1 Oncology
Todd Haim, Program Director, NIH, National Cancer Institute, Small Business Innovation Research (SBIR) Development Center

#2 Immunology
Kia Motesharei, Head, Global Licensing & Business Development, Immunology, Merck KGaA, Darmstadt, Germany

#3 Immuno-oncology
Paul Resnick, Vice President and Chief Business Officer, MabVax Therapeutics, Inc.

#4 Rare and Orphan Diseases

Joe Whalen, Senior Vice President, Business Development & Alliance Management, Horizon Pharma

#5 Pain

Kathryn Gregory, Executive Director, Business Development, Purdue Pharma

#6 Gene Therapy
Jeremy Ahouse, Executive Director, Business Development & Global Alliances, Celgene

#7 Diabetes
Christoph Pittius, Vice President, Head of Transactions, AstraZeneca

#8 Neurodegenerative Diseases

Todd Haim

Program Director
NIH, National Cancer Institute, Small Business Innovation Research (SBIR) Development Center

See Bio

Joe Whalen

Senior Vice President, Business Development and Alliance Management
Horizon Pharma

See Bio

Kia Motesharei

Head, Global Licensing & Business Development, Immunology
EMD Serono / Merck KGaA

See Bio

Paul Resnick

Vice President and Chief Business Officer
MabVax Therapeutics

See Bio

Kathryn Gregory

Executive Director, Business Development
Purdue Pharma

See Bio

09:20 - 09:35 Biotech Spotlight | Heracles Pharma

Speaker:
Jim Vail Director of Business Development Heracles Pharma

Jim Vail

Director of Business Development
Heracles Pharma

See Bio

09:35 - 09:50 Biotech Spotlight | Sorrento Therapeutics

Speaker:
Henry Ji President and Chief Executive Officer Sorrento Therapeutics

Henry Ji

President and Chief Executive Officer
Sorrento Therapeutics

See Bio

General Session

09:50 - 10:30 Panel Discussion | Going beyond PD-1 and PD-L1, Future Opportunities in Immunotherapies

Speakers:
Prakash Raman Vice President, Global Head of Oncology BD&L Novartis
Christian Hordo Head of Business Development Juno Therapeutics
Paul Resnick Vice President and Chief Business Officer MabVax Therapeutics
Michael Woo Director, Search & Evaluation, ImmunoOncology Merck KGaA, Darmstadt, Germany
Moderator:
Michelle B. Hoffmann Senior Vice President Back Bay Life Science Advisors

• What are the latest opportunities for immunology in areas such as cell therapy?
• Just how many immunotherapies can you put checkpoints on top of?
• What are the newest opportunities for combination therapies in immunology?

Prakash Raman

Vice President, Global Head of Oncology BD&L
Novartis

See Bio

Christian Hordo

Head of Business Development
Juno Therapeutics

See Bio

Paul Resnick

Vice President and Chief Business Officer
MabVax Therapeutics

See Bio

Michael Woo

Director, Search & Evaluation, ImmunoOncology
Merck KGaA, Darmstadt, Germany

See Bio

Michelle B. Hoffmann

Senior Vice President
Back Bay Life Science Advisors

See Bio

1:1 Partnering Meetings

09:50 - 10:30 Opening Of 1:1 Partnering Meetings

General Session

10:30 - 11:00 Networking And Refreshment Break

1:1 Partnering Meetings

10:30 - 11:00 Opening Of 1:1 Partnering Meetings

General Session

11:00 - 11:40 Panel Discussion | Current and Future Opportunities in Gene and Cell Therapies

Moderator:
Hemmie Chang Chair, Licensing & Strategic Alliances Practice Group Foley Hoag
Speakers:
Simon Bateman Executive Director, Business Development & Licensing, Alliance Management Novartis
Jeremy Ahouse Executive Director, Alliance Management Celgene Corporation
Lawrence Klein Vice President, Strategy CRISPR Therapeutics

• Which areas are ripe for cell and gene therapy, which areas are inapplicable?
• How are new deals being developed for these new technologies?
• With a curative approach, what is the future for cell and gene therapy?

Hemmie Chang

Chair, Licensing & Strategic Alliances Practice Group
Foley Hoag

See Bio

Simon Bateman

Executive Director, Business Development & Licensing, Alliance Management
Novartis

See Bio

Jeremy Ahouse

Executive Director, Alliance Management
Celgene Corporation

See Bio

Lawrence Klein

Vice President, Strategy
CRISPR Therapeutics

See Bio

1:1 Partnering Meetings

11:00 - 11:40 Opening Of 1:1 Partnering Meetings

General Session

11:40 - 11:45 NCI Introduction

Speaker:
Todd Haim Program Director NIH, National Cancer Institute, Small Business Innovation Research (SBIR) Development Center

Todd Haim

Program Director
NIH, National Cancer Institute, Small Business Innovation Research (SBIR) Development Center

See Bio

1:1 Partnering Meetings

11:40 - 11:45 Opening Of 1:1 Partnering Meetings

General Session

11:45 - 12:00 Biotech Spotlight | CellSight

Speaker:
Aruna Gambhir Chief Executive Officer CellSight

Hear from innovative oncology focused biotech companies who will provide a 15 minute overview of their latest technologies. Find out the latest innovations that could be critical to your next deal, or demonstrate your technology to an audience looking for their next deal.

Aruna Gambhir

Chief Executive Officer
CellSight

See Bio

1:1 Partnering Meetings

11:45 - 12:00 Opening Of 1:1 Partnering Meetings

General Session

12:00 - 12:15 Biotech Spotlight | CerRx

Speaker:
Bill Simpson Chief Executive Officer CerRx

Bill Simpson

Chief Executive Officer
CerRx

See Bio

1:1 Partnering Meetings

12:00 - 12:15 Opening Of 1:1 Partnering Meetings

General Session

12:15 - 12:30 Biotech Spotlight | Humanetics

Speaker:
Ron Zenk Chief Executive Officer Humanetics

Ron Zenk

Chief Executive Officer
Humanetics

See Bio

1:1 Partnering Meetings

12:15 - 12:30 Opening Of 1:1 Partnering Meetings

General Session

12:30 - 12:45 Biotech Spotlight | JSK Therapeutics

Speaker:
Paul Shami Chief Medical Officer JSK Therapeutics

Paul Shami

Chief Medical Officer
JSK Therapeutics

See Bio

1:1 Partnering Meetings

12:30 - 12:45 Opening Of 1:1 Partnering Meetings

General Session

12:45 - 13:00 Biotech Spotlight | Keystone Nano

Speaker:
Jeff Davidson Chief Executive Officer Keystone Nano

Jeff Davidson

Chief Executive Officer
Keystone Nano

See Bio

1:1 Partnering Meetings

12:45 - 13:00 Opening Of 1:1 Partnering Meetings

13:00 - 14:00 Networking Luncheon

General Session

14:00 - 14:40 Panel Discussion | The Equities Market of 2016, What is Possible?

Speakers:
Joe Whalen Senior Vice President, Business Development and Alliance Management Horizon Pharma
Timothy Morris Chief Financial Officer, Head of Business Development AcelRx Pharmaceuticals Inc
Robert Breuil Chief Financial Officer Corium International, Inc.
Moderator:
Luke Düster Managing Director CRG

• Where can you find money in public markets currently?
• What creative financing is being done?
• How are companies finding money to launch?

Joe Whalen

Senior Vice President, Business Development and Alliance Management
Horizon Pharma

See Bio

Timothy Morris

Chief Financial Officer, Head of Business Development
AcelRx Pharmaceuticals Inc

See Bio

Robert Breuil

Chief Financial Officer
Corium International, Inc.

See Bio

Luke Düster

Managing Director
CRG

See Bio

1:1 Partnering Meetings

14:00 - 14:40 1:1 Partnering Meetings

General Session

14:40 - 15:20 Panel Discussion | Successfully Capturing the Attention of Big and Mid-Sized Pharma

Speakers:
Monica Viziano Senior Director, Alliance Management, Corporate Development Gilead Sciences
Kia Motesharei Head, Global Licensing & Business Development, Immunology EMD Serono / Merck KGaA
Neil Berkley Senior Director, Business Development GSK
Kevin Anderson Director, Global Business Development, Immunology, Inflammation & Infectiou Roche
Klaus Damm Director, Search and Evaluation, Oncology Abbvie
Moderator:
Greg Benning Managing Director, Head of Financial Advisory Back Bay Life Science Advisors

• What are the top 5 do’s and don’ts for the pitch deck?
• What is the process for getting on their radar?
• How do you effectively progress discussions?

Monica Viziano

Senior Director, Alliance Management, Corporate Development
Gilead Sciences

See Bio

Kia Motesharei

Head, Global Licensing & Business Development, Immunology
EMD Serono / Merck KGaA

See Bio

Neil Berkley

Senior Director, Business Development
GSK

See Bio

Greg Benning

Managing Director, Head of Financial Advisory
Back Bay Life Science Advisors

See Bio

Kevin Anderson

Director, Global Business Development, Immunology, Inflammation & Infectiou
Roche

See Bio

Klaus Damm

Director, Search and Evaluation, Oncology
Abbvie

See Bio

1:1 Partnering Meetings

14:40 - 15:20 1:1 Partnering Meetings

General Session

15:20 - 15:50 Networking And Refreshment Break

1:1 Partnering Meetings

15:20 - 15:50 1:1 Partnering Meetings

General Session

15:50 - 16:05 Biotech Spotlight | Signpath Pharma

Speaker:
Kai Larson Vice President, Business Development, COO Signpath Pharma

Kai Larson

Vice President, Business Development, COO
Signpath Pharma

See Bio

1:1 Partnering Meetings

15:50 - 16:05 1:1 Partnering Meetings

General Session

16:05 - 16:20 Biotech Spotlight | Paranta Biosciences

Speaker:
Ross Barrow Chief Executive Officer Paranta Biosciences

Ross Barrow

Chief Executive Officer
Paranta Biosciences

See Bio

1:1 Partnering Meetings

16:05 - 16:20 1:1 Partnering Meetings

General Session

16:20 - 16:35 Biotech Spotlight

Speaker:
Wonsuk Yang Chief Executive Officer GtreeBNT Co., Ltd.

Wonsuk Yang

Chief Executive Officer
GtreeBNT Co., Ltd.

See Bio

1:1 Partnering Meetings

16:20 - 16:35 1:1 Partnering Meetings

General Session

16:35 - 16:50 Biotech Spotlight | Tapimmune

Speaker:
John Bonfiglio President & COO Tapimmune

John Bonfiglio

President & COO
Tapimmune

See Bio

1:1 Partnering Meetings

16:35 - 16:50 1:1 Partnering Meetings

General Session

16:50 - 17:30 Panel Discussion | Establishing Innovation Hubs to Build the Pipeline

Moderator:
Chris Leo SVP Back Bay Life Science Advisors
Speakers:
Neena Kadaba Director, Industry Alliances QB3
Barbara Araneo Innovation Sourcing Director Novo Nordisk
Melinda Richter Head of JLABS Janssen R&D US
Alex Szidon Executive Director, Business Development & Licensing, Head, West Coast Inno Merck
Heather Wasserman Senior Director Eli Lilly and Company

• How do different innovation hubs compete or differentiate themselves?
• What is the role of geography and how can geography be used for advantage?
• What is next on the horizon for innovation centers?